Abstract:Over the past decade, there has been growing interest in the use of antibodies against intracellular targets. This is currently achieved through recombinant expression of the single chain variable fragment (scFv) antibody format within the cell, which is commonly referred to as an intrabody. This possesses a number of inherent advantages over RNA interference (iRNA). Firstly, the high specificity and affinity of intrabodies to target antigens is well-established, whereas iRNA has been frequently shown to exert multiple non-specific effects. Secondly, intrabodies being proteins possess a much longer active half-life compared to iRNA. Thirdly, when the active half-life of the intracellular target molecule is long, gene silencing through iRNA would be slow to yield any effect, whereas the effects of intrabody expression would be almost instantaneous. Lastly, it is possible to design intrabodies to block certain binding interactions of a particular target molecule, while sparing others. There is, however, various technical challenges faced with intrabody expression through the application of recombinant DNA technology. In particular, protein conformational folding and structural stability of the newly-synthesized intrabody within the cell is affected by reducing conditions of the intracellular environment. Also, there are overwhelming safety concerns surrounding the application of transfected recombinant DNA in human clinical therapy, which is required to achieve intrabody expression within the cell. Of particular concern are the various viral-based vectors that are commonly-used in genetic manipulation. A novel approach around these problems would be to look at the possibility of fusing protein transduction domains (PTD) to scFv antibodies, to create a ‘cell-permeable’ antibody or ‘Transbody’. PTD are short peptide sequences that enable proteins to translocate across the cell membrane and be internalized within the cytosol, through atypical secretory and internalization pathways. There are a number of distinct advantages that a ‘Transbody’ would possess over conventional intrabodies expressed within the cell. For a start, ‘correct’ conformational folding and disulfide bond formation can take place prior to introduction into the target cell. More importantly, the use of cell-permeable antibodies or ‘Transbodies’ would avoid the overwhelming safety and ethical concerns surrounding the direct application of recombinant DNA technology in human clinical therapy, which is required for intrabody expression within the cell. ‘Transbodies’ introduced into the cell would possess only a limited active half-life, without resulting in any permanent genetic alteration. This would allay any safety concerns with regards to their application in human clinical therapy.

Development of a spermine lipid for transient antibody expression

Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: Potential advantages over antibodies expressed within the intracellular environment (Intrabody)

Development of a Hybrid Biomimetic Ligand with High Selectivity and Mild Elution for Antibody Purification

Development of a disposable micro-capillary film grafted with peptide ligands for immunoadsorption.

A Strategy to Improve Serum-Tolerant Transfection Activity of Polycation Vectors by Surface Hydroxylation

Maximizing Antibody Production in Suspension-Cultured Mammalian Cells by the Customized Transient Gene Expression Method

EPISOMAL VECTORS FOR STABLE PRODUCTION OF RECOMBINANT PROTEINS AND ENGINEERED ANTIBODIES

Rapid generation of high-quality recombinant antibodies using an Expi293F expression system for a 17 β-estradiol immunoassay

Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.

Optimization of a transient antibody expression platform towards high titer and efficiency

Exploring Parametric and Mechanistic Differences between Expi293FTM and ExpiCHO-STM Cells for Transient Antibody Production Optimization

Efficient mAb production in CHO cells incorporating PEI-mediated transfection, mild hypothermia and the co-expression of XBP-1

High titer expression of antibodies using linear expression cassettes for early-stage functional screening

Cost-Effective Protein Production in CHO Cells Following Polyethylenimine-Mediated Gene Delivery Showcased by the Production and Crystallization of Antibody Fabs

Development of Novel Lipoplex Formulation Methodologies to Improve Large Scale Transient Transfection for Lentiviral Vector Manufacture

An antifouling membrane-fusogenic liposome for effective intracellular delivery in vivo

Development of a protein-solubilizing expression method based on the synergistic action of intein ΔI-CM and the solubility enhancer elastin-like polypeptide

Cell-Permeant Bioadaptors for Cytosolic Delivery of Native Antibodies: A “Mix-and-Go” Approach

Optimizing Transfection Efficiency of Spermine Polar Head Cholesterol‐based Cationic Lipids with Amino Acid Linker

Synergistic promotion of transient transgene expression in CHO cells by PDI/XBP-1s co-transfection and mild hypothermia

Esterase‐Labile Quaternium Lipidoid Enabling Improved mRNA‐LNP Stability and Spleen‐Selective mRNA Transfection